公开(公告)号：WO2002020090A3

公开(公告)日：2002-03-14

申请号：PCT/EP2001/010448

申请日：2001-09-10

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  BATEMAN, Simon, David ,  GIMONA, Alberto ,  HOLINEJ, Jurij ,  HUELS, Jasper ,  JAYAWARDENE, Sumedha ,  KARABELAS, Argeris, Jerry ,  KHALED, Maha, Y. ,  KARNACHI, Anees, Abdulquadar ,  NIC LOCHLAINN, Eimear, Mairin ,  MACERATA, Richard ,  SLOAN, Victor

Inventor： BATEMAN, Simon, David ,  GIMONA, Alberto ,  HOLINEJ, Jurij ,  HUELS, Jasper ,  JAYAWARDENE, Sumedha ,  KARABELAS, Argeris, Jerry ,  KHALED, Maha, Y. ,  KARNACHI, Anees, Abdulquadar ,  NIC LOCHLAINN, Eimear, Mairin ,  MACERATA, Richard ,  SLOAN, Victor

IPC: A61P5/00

Abstract: A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising: 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 hours.

公开(公告)号：WO0220090A9

公开(公告)日：2003-10-30

申请号：PCT/EP0110448

申请日：2001-09-10

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

Inventor： BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

IPC: A61K47/02 ,  A61K9/20 ,  A61K9/28 ,  A61K31/195 ,  A61K31/196 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P5/00 ,  A61P29/00 ,  A61P43/00

CPC classification number: A61K31/195 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/196

Abstract: A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising: 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 hours.

Abstract translation: 一种用于治疗环氧合酶-2依赖性病症或病症的组合物，其包含：5-甲基-2（2'-氯-6'-氟苯胺基）苯乙酸或其药学上可接受的盐，该组合物是用于治疗 所述疾病或病症约24小时。

公开(公告)号：WO2003020261A1

公开(公告)日：2003-03-13

申请号：PCT/EP2002/009701

申请日：2002-08-30

Applicant: NOVARTIS AG ,  NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. ,  KARNACHI, Anees Abdulquadar ,  BATEMAN, Simon, David

Inventor： KARNACHI, Anees Abdulquadar ,  BATEMAN, Simon, David

IPC: A61K31/196

CPC classification number: A61K31/196

Abstract: Disclosed herein tablets and methods of treatment comprising the administration of such tablets. The tablets are immediate release tablets that comprise about 400 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, where the 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof comprises between 60 and 70% by weight of the tablet. The methods involve the administration of the tablets of the invention to individuals in need of administration of such tablets.

Abstract translation: 本文公开了包含施用此类片剂的片剂和治疗方法。 片剂是包含约400mg 5-甲基-2-（2'-氯-6'-氟苯胺基）苯乙酸或其药学上可接受的盐的速释片剂，其中5-甲基-2-（2'- 氯代-6'-氟苯胺基）苯乙酸或其药学上可接受的盐占片剂重量的60-70％。 所述方法包括将本发明的片剂给予需要施用此类片剂的个体。

公开(公告)号：WO2003074041A1

公开(公告)日：2003-09-12

申请号：PCT/EP2003/002322

申请日：2003-03-06

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  KARNACHI, Anees Abdulquadar ,  KHALED, Maha, Y. ,  HOLINEJ, Jurij ,  JOSHI, Yatindra

Inventor： KARNACHI, Anees Abdulquadar ,  KHALED, Maha, Y. ,  HOLINEJ, Jurij ,  JOSHI, Yatindra

IPC: A61K31/196

CPC classification number: A61K9/2095 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2866 ,  A61K31/195 ,  A61K31/196

Abstract: A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid in an amount effective to treat such a disorder or condition for about 24 hours, comprising administering orally once a day to a human in need of such treatment one or more immediate release pharmaceutical compositions comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid , and compositions suitable for use in such methods.

Abstract translation: 一种治疗环加氧酶-2依赖性病症或病症的方法，包括以有效治疗这种病症或病症的量施用5-甲基-2-（2'-氯-6'-氟苯胺基）苯乙酸约24小时，包括 每天口服一次给予需要这种治疗的人一种或多种包含5-甲基-2-（2'-氯-6'-氟苯胺基）苯乙酸的立即释放药物组合物，以及适用于这些方法的组合物。

公开(公告)号：WO0220090A2

公开(公告)日：2002-03-14

申请号：PCT/EP0110448

申请日：2001-09-10

Applicant: NOVARTIS AG ,  NOVARTIS ERFIND VERWALT GMBH ,  BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

Inventor： BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

IPC: A61K47/02 ,  A61K9/20 ,  A61K9/28 ,  A61K31/195 ,  A61K31/196 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P5/00 ,  A61P29/00 ,  A61P43/00

CPC classification number: A61K31/195 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/196

Abstract: A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising: 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 hours.

Abstract translation: 一种用于治疗环氧合酶-2依赖性病症或病症的组合物，其包含：5-甲基-2（2'-氯-6'-氟苯胺基）苯乙酸或其药学上可接受的盐，该组合物是用于治疗 所述疾病或病症约24小时。

公开(公告)号：WO0121159A2

公开(公告)日：2001-03-29

申请号：PCT/EP0009074

申请日：2000-09-15

Applicant: NOVARTIS AG ,  NOVARTIS ERFIND VERWALT GMBH ,  GATLIN MARJORIE REGAN ,  PONGOWSKI MICHELE ,  MANNION RICHARD OWEN ,  KARNACHI ANEES ABDULQUADAR ,  GUITARD CHRISTIANE ,  ALLISON MALCOLM

Inventor： GATLIN MARJORIE REGAN ,  PONGOWSKI MICHELE ,  MANNION RICHARD OWEN ,  KARNACHI ANEES ABDULQUADAR ,  GUITARD CHRISTIANE ,  ALLISON MALCOLM

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/195 ,  A61K31/198 ,  A61K31/425 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/63 ,  A61K31/64 ,  A61K38/28 ,  A61K47/04 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P1/00 ,  A61P1/04 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/00 ,  A61P19/02 ,  A61P19/10 ,  A61P27/06 ,  A61P27/12 ,  A61K31/00

CPC classification number: A61K31/44 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/195 ,  A61K31/198 ,  A61K31/425 ,  A61K31/64 ,  A61K31/155 ,  A61K2300/00

Abstract: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the uses of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

Abstract translation: 本发明涉及分别包含那格列奈（I）或瑞格列奈和至少一种选自噻唑烷二酮衍生物（格列酮），磺酰脲衍生物和二甲双胍的其它抗糖尿病化合物的组合，例如组合制剂或药物组合物 用于预防，延迟进展或治疗疾病，特别是代谢紊乱，特别是2型糖尿病和与糖尿病相关的疾病和病症的同时，单独或顺序使用; 涉及包含那格列奈和药学上可接受的载体的组合物和制备该组合物的方法; 使用这种组合或组合物来制备用于预防，延缓进展或治疗代谢紊乱的药物; 一种预防，延缓进展或治疗温血动物疾病的方法; 这种组合或组合物用于化妆品处理哺乳动物以实现化妆品有益的体重损失; 以及改善温血动物的身体外观的方法。